Related Experiment Video
Updated: Sep 10, 2025

Fetal Mouse Cardiovascular Imaging Using a High-frequency Ultrasound 30/45MHZ System
Published on: May 5, 2018
Risk factors for maternal cardiac and obstetric outcomes in patients with and without CHD
Ciara Brown1, Sarah Voskamp2, Alicia Kube3
1George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
Insights
Women with congenital heart disease (CHD) face higher risks of cardiac and obstetric complications during pregnancy. Their hospital stays are also longer, influenced by the severity of their heart condition.
Area of Science:
- Cardiology
- Obstetrics
- Maternal-Fetal Medicine
Background:
- Peripartum physiological changes increase morbidity risk for women with congenital heart disease (CHD).
- This study compares peripartum complications and length of stay in women with and without CHD.
Purpose of the Study:
- To examine factors associated with peripartum complications in women with CHD.
- To compare length of stay for women with and without CHD during the peripartum period.
Main Methods:
- Retrospective case-control study of women with CHD and a control group (2000-2017).
- Analysis of clinical and echocardiographic data to assess baseline characteristics, disease severity, and adverse outcomes.
- Multivariable regression to evaluate the relationship between maternal CHD, characteristics, and peripartum events.
Main Results:
- Women with CHD had higher rates of cardiac complications (e.g., arrhythmia) and obstetric events (e.g., caesarean delivery).
- Increasing maternal age correlated with increased composite cardiac events.
- Hospital length of stay was significantly longer for women with CHD and associated with disease severity.
Conclusions:
- Women with CHD experience greater cardiac and obstetric morbidity during peripartum admissions.
- Increased length of hospital stay in women with CHD is linked to their underlying heart disease severity.
Background:
Physiologic changes in the peripartum period put women with CHD at increased risk for morbidity. This study examines factors associated with peripartum complications and length of stay compared to patients without CHD.
Methods:
This single-institution retrospective case-control study included women with CHD (2000-2017) and a control population without CHD. A review of clinical and echocardiographic data was used to assign baseline characteristics, disease severity, and adverse outcomes. Primary outcomes were composite variables of cardiac and obstetric adverse events, along with peripartum length of stay. The relationship between maternal CHD, baseline characteristics, and peripartum adverse events was evaluated by multivariable regression.
Results:
The cohort and control groups included 162 deliveries among 113 women and 321 deliveries among 321 women, respectively. Cardiac complications, including arrhythmia, heart failure, pulmonary oedema, and thromboembolic events, occurred in 8.6% of the cohort (RR 2.52, 95% CI 1.17-5.42), with the most common event being arrhythmia. Obstetric events, such as caesarean delivery, assisted vaginal delivery, preterm birth, and pre-eclampsia, occurred in 67.9% versus 56.1% in the control group (RR 1.21, 95% CI 1.05-1.40). In multivariable models, increasing age was associated with increased composite cardiac events. Length of stay was longer in the cohort group (p < 0.001) and significantly associated with modified World Health Organization classification (p = 0.016).
Conclusions:
Women with CHD experience increased cardiac and obstetric morbidity compared to controls during peripartum admission. Those with CHD have longer hospital stays around delivery, which is associated with disease severity.
Related Concept Videos
Pathophysiology of Cardiac Performance
Mitral Valve Prolapse III: Nursing Management
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
Heart Failure I: Introduction
Mitral Stenosis I: Introduction
Cardiomyopathy III: Hypertrophic Cardiomyopathy

